| ribavirin / Generic mfg. |
2006-006042-33: A pilot, open label, multicenter, randomized clinical trial on Lopinavir/Ritonavir-monotherapy vs Lopinavir/Ritonavir plus selected Nucs, in HIV/HCV coinfected patients with chronic hepatitis C or compensated cirrhosis, starting treatment with Ribavirin and Pegylated Interferon |
|
|
| Ongoing | 3 | 50 | Europe | KALETRA, COPEGUS, PEGASYS, KALETRA, COPEGUS, PEGASYS | OSPEDALE S. RAFFAELE | patients affected by HIV and chronic HCV or compensated cirrhosis | | | | |
2006-005996-17: A pilot, open label, multicenter, randomized clinical trial on Lopinavir/ritonavir-monotherapy vs Lopinavir/ritonavir plus selected Nucs, in HIV/HCV ARV-naive coinfected patients with chronic hepatitis C or compensated cirrhosis, starting treatment with Ribavirin and Pegylated Interferonﾔ |
|
|
| Ongoing | 3 | 60 | Europe | KALETRA, PEGASYS, COPEGUS, KALETRA, PEGASYS, COPEGUS | OSPEDALE S. RAFFAELE | PATIENTS AFFECTED BY HIV/HCV NAIVES FROM THERAPIES | | | | |
2005-003648-70: Randomised, double-blinded phase IIIb study to optimise antiviral therapy response of a standard therapy consisting of peginterferon-alfa-2a and ribavirin plus the additional use of bezafibrat 400 mg/d in untreated patients with chronic hepatits C typ 1. |
|
|
| Ongoing | 3 | 414 | Europe | Cedur retard, Pegasys, Copegus, Cedur retard, Pegasys, Copegus | Charité Universitätsmedizin Berlin | First time treatment in chronic hepatitis C-infection patients with elevated GGT-level without coinfections as HBV, HDV and HIV | | | | |
2007-000279-40: Randomised phase 3B study on comparison of 2 treatment schedules with peginterferon alpha 2b and ribavirin short term versus standard term schedules in patients with chronic hepatitis C, genotype 2 or 3 and early virologic response comparison of efficacy, tolerability, quality of life and costs. |
|
|
| Ongoing | 3 | 80 | Europe | Ribavirin, PEGINTRON, PEGINTRON | A.S.L. 2 | Patients with chronic hepatitis C with genotype 2 or 3 | | | | |
2008-006453-40: Peg-INF alfa-2a plus ribavirin treatment of liver transplant patients with hepatitis C relaps on protocol liver biopsies - a Nordic study on rapid viral response, early viral response, end of treatment response and sustained viral response rates |
|
|
| Ongoing | 3 | 100 | Europe | Pegasys, Copegus, Pegasys 180 mcg / 135 mcg, Copegus 200 mg / 400 mg, Pegasys 180 mcg / 135 mcg, Copegus 200 mg / 400 mg | Karolinska University hospital Huddinge | Chronic hepatitis C infection | | | | |
2009-018146-38: Multicenter randomized controlled study comparing the efficacy and safety of natural Multi-subtype interferon alpha (Multiferon) in association with ribavirin versus retreatment with pegylated interferon-alpha 2a and ribavirin in non-responding genotype 1 hepatitis C patients. |
|
|
| Ongoing | 3 | 110 | Europe | Multiferon, Pegasys, Copegus, Multiferon, Pegasys, Copegus | Swedish Orphan International AB | Hepatitis C | | | | |
2014-004268-38: Individual Patient Access to AbbVie ABT-450/ritopnavir/ABT-267 and ABT-333 Coadministeres with ribavirin (RBV) in Adult Liver Transplant Recipient with Genotype 1 Hepatitis C Virus Infection |
|
|
| Ongoing | 3 | 1 | Europe | ABT-450/ritonavir/ABT-267, ABT-333, | Semmelweis Egyetem Transzplantációs és Sebészeti Klinika | | | | | |
NCT03759782: Ribavirin to Enhance Hepatitis B Virus Nucleotide Analog Antiviral Activity |
|
|
| Recruiting | 3 | 24 | Canada | Ribavirin, Tenofovir | Ottawa Hospital Research Institute | Hepatitis B, Chronic | 01/22 | 09/22 | | |
| Not yet recruiting | 3 | 100 | RoW | Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :, Nanozoxide, ivermectin and ribavirin 200 mg or 400 mg | Mansoura University | COVID, Drug Effect | 05/22 | 05/22 | | |
NCT04959786: MANS-NRIZ Trial for COVID-19 Treatment : Extension Study |
|
|
| Recruiting | 2/3 | 100 | RoW | Ivermectin,ribavirin ,nitazoxanide and zinc | Mansoura University | COVID-19 Pneumonia | 11/22 | 12/22 | | |
NCT05616598: Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters |
|
|
| Completed | 2/3 | 200 | RoW | Sofosbuvir +daclatasvir+ simeprevir+Ribavirin | Benha University | Male Infertility, HCV | 11/22 | 12/22 | | |
| Not yet recruiting | 2/3 | 1755 | NA | Favipiravir, Ribavirin, Standard of care, Dexamethasone | Irrua Specialist Teaching Hospital, Alliance for International Medical Action, University of Bordeaux, Bernhard Nocht Institute for Tropical Medicine, Federal Medical Centre, Owo, Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire, Fondation pour la Recherche Scientifique, Benin, Médecins Sans Frontières, Belgium, Alex Ekwueme Federal University Teaching Hospital, Donka Hospital, Conakry, Centre de Recherche Médicale de Lambaréné, University of Hamburg-Eppendorf, Phebe Hospital, Liberia, University of North Carolina, ANRS, Emerging Infectious Diseases | Lassa Fever | 06/27 | 06/27 | | |
